-
Evidence for the Monitoring of Minimal Residual Disease Dynamics to Guide Clinical Practice in Patients with Multiple Myelom
Author: Gan, Xinai; Li, Linfeng; Zhang, Li; Zheng, Yuhuan; Niu, Ting; Yu, Zhengyu
Journal: TARGETED ONCOLOGY. 2026; Vol. , Issue , pp. -. DOI: 10.1007/s11523-026-01199-z
-
Fruquintinib Plus Sintilimab in Patients with Treatment-Naive and Previously Treated Advanced Renal Cell Carcinoma: Results from a Phase Ib/II Clinical Tria
Author: Xu, Hua; Yao, Xin; He, Zhisong; Luo, Hong; Li, Guiling; Guo, Jianming; Diao, Lei; Fan, Yu; Li, Yuan; Fan, Jiquan; Hu, Xiaoyi; Lu, Puhan; Shi, Haiyan; Chen, Keyan; Tan, Panfeng; Fan, Songhua; Shi, Michael; Su, Weiguo; Ye, Dingwei
Journal: TARGETED ONCOLOGY. 2025; Vol. , Issue , pp. -. DOI: 10.1007/s11523-024-01120-6
-
Fruquintinib Plus Sintilimab in Patients with Treatment-Naive and Previously Treated Advanced Renal Cell Carcinoma: Results from a Phase Ib/II Clinical Tria
Author: Xu, Hua; Yao, Xin; He, Zhisong; Luo, Hong; Li, Guiling; Guo, Jianming; Diao, Lei; Fan, Yu; Li, Yuan; Fan, Jiquan; Hu, Xiaoyi; Lu, Puhan; Shi, Haiyan; Chen, Keyan; Tan, Panfeng; Fan, Songhua; Shi, Michael; Su, Weiguo; Ye, Dingwei
Journal: TARGETED ONCOLOGY. 2025; Vol. 20, Issue 1, pp. 113-125. DOI: 10.1007/s11523-024-01120-6
